Dr Lucas Przymusinski > DLA Piper LLP (US) > New York, United States > Lawyer Profile

DLA Piper LLP (US)
1251 6TH AVE,
NEW YORK, NY 10020-1104
United States

Work Department

Litigation, Arbitration and Investigations; Product Liability, Mass Torts and Product Stewardship; Life Sciences




Dr. Lucas Przymusinski is an internal medicine physician and partner in DLA Piper’s Product Liability, Mass Tort and Product Stewardship group.  He focuses his practice on drug and device litigation, mass torts, product liability, and regulatory issues.

Dr. Przymusinski has led the scientific and legal defense of numerous mass tort litigations, representing some of the largest pharmaceutical and medical device manufacturers.  He has been involved in every stage of litigation, including strategic assessment and planning, motion practice, expert development, trial and appellate practice.

Dr. Przymusinski also regularly counsels life sciences clients on litigation, regulatory, risk management and mitigation, corporate governance and other product-related issues.  He also helps guide clients through the FDA Advisory Committee process and assists in developing strategic responses to product safety-issues, recalls and related FDA enforcement actions.


English, Polish


J.D., Duke University School of Law; M.D., Albany Medical College; B.S., Duke University

Lawyer Rankings

United States > Industry focus > Healthcare: life sciences

(Next Generation Partners)

Lucas PrzymusinskiDLA Piper LLP (US)

United States > Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices

The ‘extremely responsive and thoughtful’ team at DLA Piper LLP (US) provides an ‘excellent client service and medical device knowledge’ to a wide range of pharmaceuticals companies, including Sanofi and Bayer, across a range of major product liability mandates. While the firm has a growing profile in trying cases, it is particularly adept at achieving an early conclusion of cases, through its effective use of dispositive pre-emption motions and Daubert challenges. Loren Brown in New York regularly acts as national co-ordinating counsel and lead trial counsel in mass torts and MDLs throughout the country, as well as in the context of global litigation – including her work for Bayer in mass tort litigation involving Essure. Based out of Atlanta, product liability chair Christopher Campbell is noted for his high-level strategic advice to manufacturers across a range of products, including many within the pharmaceutical space, where he is appreciated for his ‘guidance on the big picture’, as well his aptitude at handling cross-border mandates. Boston-based global co-chair of the firm’s life sciences sector, Matthew Holian is ‘super smart and very strategic‘ throughout the product life cycle, from risk assessment, pre-litigation discovery, bellwether trials and, ultimately, resolution. ‘Highly-skilled‘ Boston-based Katie Insogna excels at handling high-stakes litigation and counselling. Based out New York, Lucas Przymusinski provides ‘thoughtful guidance‘ to pharma companies across an array of regulatory and litigation matters, including product liability disputes, where his medical and science background provides additional benefit.